Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MNKD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Technosphere® Insulin Inhalation System | Diabetes | N/A · NCT01459133 | Withdrawn |
| Rapid-acting Insulin Analog | Diabetes Mellitus, Type 1 | Phase 4 · NCT05904743 | Completed |
| Insulin Human | Diabetes Mellitus, Type 1 | Phase 4 · NCT05904743 | Completed |
| Afrezza (insulin human) Inhalation Powder | Type 1 Diabetes | Phase 4 · NCT05243628 | Completed |
| Afrezza Inhalant Product | Type 2 Diabetes Treated With Insulin | Phase 4 · NCT04125082 | Unknown |
| Basal Insulin | Diabetes Mellitus, Type 1 | Phase 4 · NCT05904743 | Completed |
| Technosphere® Insulin with MedTone C Inhaler | Type 1 Diabetes Mellitus | Phase 3 · NCT01445951 | Completed |
| Technosphere Insulin Inhalation Powder | Type 2 Diabetes | Phase 3 · NCT01196104 | Terminated |
| Technosphere ®Insulin with Gen2 Inhaler | Type 1 Diabetes Mellitus | Phase 3 · NCT01445951 | Completed |
| Technosphere Insulin & Metformin | Diabetes Mellitus, Type 2 | Phase 3 · NCT00332488 | Completed |
| Metformin & Secretagogues | Diabetes Mellitus, Type 2 | Phase 3 · NCT00332488 | Completed |
| Insulin Aspart in combination with a basal… | Type 1 Diabetes Mellitus | Phase 3 · NCT01445951 | Completed |
| Inhaled Technosphere Insulin | Diabetes, Gestational | Phase 2/3 · NCT06535789 | Completed |
| Technosphere Powder | Type 2 Diabetes | Phase 3 · NCT01451398 | Completed |
| Clofazimine Inhalation Suspension | MAC Lung Disease | Phase 3 · NCT06418711 | Terminated |
| Active Comparator: 6.0mg GRI-0621 | Diabetes, Type I | Phase 3 · NCT00308308 | Completed |
Also used in these trials (approved or third-party drugs, not MNKD's own candidates): Insulin Degludec, Insulin Aspart, Insulin Lispro, Insulin Glargine, Methacholine Chloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MNKD holds $96.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $26.5M/quarter from operations, an estimated runway of 11 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MNKD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Rubric Capital Management LP | Institution (13G, 5%+) | 18,000,000 | 5.60% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 15,450,421 | 4.80% | 2026-06-30 |
| Michael Castagna Chief Executive Officer, Director · +877,275 options |
Insider | 2,433,779 | 0.76% | 2026-07-15 |
| Stuart A Tross Chief People & Workpl Officer · +265,143 options |
Insider | 1,058,142 | 0.33% | 2026-07-15 |
| David Thomson EVP Genl Counsel & Secretary · +254,525 options |
Insider | 797,554 | 0.25% | 2026-07-15 |
| Steven B. Binder Director · +127,806 options |
Insider | 713,258 | 0.22% | 2026-09-25 |
| Sanjay R Singh EVP Technical Operations · +217,000 options |
Insider | 478,966 | 0.15% | 2026-07-15 |
| Dominic Marasco Pres, Endocrine Business Unit |
Insider | 343,398 | 0.11% | 2026-07-15 |
| Christopher B Prentiss Chief Financial Officer · +438,000 options |
Insider | 318,668 | 0.10% | 2026-07-15 |
| Anthony C Hooper Director · +16,556 options |
Insider | 236,153 | 0.07% | 2026-03-01 |
| Ronald J Consiglio Director · +16,556 options |
Insider | 132,342 | 0.04% | 2026-05-20 |
| Jennifer Grancio Director · +82,781 options |
Insider | 110,701 | 0.03% | 2026-05-20 |
Share count 321,640,118 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-05-29 | Afrezza | NDA | +30.5% | +3.6% | -3.3% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MNKD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →